Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Hans_Schambye
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:country |
gptkb:Denmark
|
| gptkbp:developedBy |
galectin modulators
|
| gptkbp:focusesOn |
gptkb:cancer
inflammatory diseases fibrosis |
| gptkbp:foundedYear |
2011
|
| gptkbp:headquartersLocation |
gptkb:Copenhagen,_Denmark
|
| https://www.w3.org/2000/01/rdf-schema#label |
Galecto Biotech
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:product |
gptkb:GB0139
gptkb:GB1211 gptkb:GB2064 |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:GLTO
|
| gptkbp:website |
https://galecto.com/
|
| gptkbp:bfsParent |
gptkb:Sunstone_Life_Science_Ventures
|
| gptkbp:bfsLayer |
7
|